Scopulariopsis/Microascus Isolation in Lung Transplant Recipients: A Report of Three Cases and a Review of the Literature.

Scopulariopsis/Microascus Isolation in Lung Transplant Recipients: A Report of Three Cases and a Review of the Literature.

Mycoses. 2019 Jun 05;:

Authors: Huang L, Chen W, Guo L, Zhao L, Cao B, Liu Y, Lu B, Li B, Chen J, Wang C

Abstract
BACKGROUND: The current knowledge of invasive Scopulariopsis/Microascus infection in lung transplantationhasbeen derived from only four case reports. Although these fungi are uncommon compared with Aspergillus, they are highly resistant to the current antifungal agents, and the mortality is extremely high.
OBJECTIVES: To explore the risk factors, clinical manifestations, notable diagnostic characteristics and outcomes of positive Scopulariopsis/Microascusisolation in lung transplantation patients.
METHODS: We included all cases with positive Scopulariopsis/Microascus isolation from lower respiratory tractsor bronchial mucosa biopsiesin our lung transplantation centre. Proven cases from the literature were added.
RESULTS: Positive isolation occurred in 2% (3/157) in our centre. Four cases from the literature were added.The mortality could be considered as high as 80%, once the two cases of colonization were excluded. The average interval between transplantation and positiveisolation was 106 (19-131) days. A total of 57.1% of patients had experienced a combination of infection with Aspergillus or other fungi as well as long-term azole antifungal agent treatment before the positive isolation, which may be possible risk factors. The combination of micafungin, posaconazole and terbinafine may be an effective treatment.
CONCLUSIONS: The peak time of positive isolation was consistent with that of some opportunistic pathogens, and the possible risk factors were the infection of other fungi as well as prior long-term azole antifungal administration. In addition toits high mortality, Scopulariopsis/Microascus was also highly resistant to common antifungal agents and the combination of two or three drugs for therapy was recommended.

PMID: 31166635 [PubMed – as supplied by publisher]

Source: Industry